Skip to main content
ARTIVION, INC. logo

ARTIVION, INC. — Investor Relations & Filings

Ticker · AORT ISIN · US2289031005 LEI · 549300YTKV8DMSMG6K81 US Manufacturing
Open in API
Filings indexed 1,531 across all filing types
Latest filing 2024-09-06 Regulatory Filings
Country US United States of America
Listing US AORT

About ARTIVION, INC.

https://artivion.com/

Artivion, Inc. is a medical device company focused on developing, manufacturing, and distributing solutions for cardiac and vascular surgery. The company has an intentional focus on creating technologies to treat diseases of the aorta. In collaboration with surgeons, Artivion develops products designed to address complex surgical challenges. Its portfolio includes a range of aortic-centric technologies, such as heart valve solutions, implantable human tissues (allografts), surgical sealants, and various stent grafts for the aortic arch, thoracoabdominal, abdominal, and peripheral aorta. The company's purpose is to provide simple, elegant solutions that improve surgical outcomes for patients with aortic diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, form names, fiscal period dates, or document titles that would allow identification of a specific filing type. The text does not include any indication of being a report, announcement, certification, or any other recognizable financial or corporate filing document. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which serves as a general category for miscellaneous filings that do not fit into other specific categories.
2024-09-06 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from the company's General Counsel responding to comments from the SEC staff regarding the company's Definitive Proxy Statement on Schedule 14A filed earlier in the year. The letter addresses specific SEC comments about disclosures in the proxy statement, including pay versus performance disclosure and company-selected financial measures. The document does not contain the proxy statement itself but is a regulatory correspondence related to it. Given the nature of the document as a response letter to SEC comments on a proxy statement, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other specific categories.
2024-08-28 English
FORM 4
Director's Dealing
2024-08-27 English
Regulatory Filings 2024
Regulatory Filings
2024-08-26 English
FORM 4
Director's Dealing
2024-08-19 English
Regulatory Filings 2024
Regulatory Filings
2024-08-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.